IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
BNTX News
Archived Headlines
- Cancer-focused mRNA developer BioNTech prices IPO at the $15 low end of the range 10/10/19
- BioNTech IPO Gets Valuation Haircut 10/09/19
- BioNTech cuts share offering and lowers proposed range to $15 to $16 10/09/19
- US IPO Week Ahead: 2 billion-dollar biotechs and a bank 10/04/19
- 5 biotech IPOs are pricing tonight with 2 more on the calendar 10/02/19
See more
Biotech IPOs close to beating Covid-19
Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in December 2018. However, BioNTech (BNTX), an October 2019 IPO, and Pfizer may be first to get FDA approval. Vir...read more
US IPO Week Ahead: Another biotech plans to take on the IPO market
Biotechs are back as another early stage biotech, Keros Therapeutics (KROS), plans to take on the IPO market in the week ahead, following last week's successful debut of Zentalis Pharmaceuticals (ZNTL). Keros Therapeutics, a Phase 1 biotech developing novel treatments for hematological and musculoskeletal disorders, plans to raise...read more
US IPO Weekly Recap: Two big biotechs and a bank squeeze through the IPO window
Three IPOs raised a combined $426 million this week, all pricing below the midpoint and finishing below issue. On average they returned a disappointing -13.5%. Despite lopping $1 billion off of its proposed valuation, Germany-based BioNTech (BNTX) became the ...read more
BioNTech's IPO values it at $3.4 billion in one of the largest biotech listings of all time
German immunotherapy developer BioNTech (BNTX) raised $150 million in a US IPO that values the company at $3.4 billion. Despite pricing below its last round, BioNTech is the third-largest biotech to list in the past decade. BioNTech is the latest in a series of large biotechs going public in the US. Along with immunotherapy developers Moderna and Genmab, the...read more